June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Allogeneic immunosafe plasma rich in growth factors as an alternative therapy in patients with refractory ocular surface disorders
Author Affiliations & Notes
  • Rosa Alvarado
    Instituto Universitario Fernandez-Vega, Oviedo, Spain
  • Belen Alfonso-Bartolozzi
    Instituto Universitario Fernandez-Vega, Oviedo, Spain
  • Jose F Alfonso
    Instituto Universitario Fernandez-Vega, Oviedo, Spain
  • Luís Fernández-Vega-Cueto
    Instituto Universitario Fernandez-Vega, Oviedo, Spain
  • Jesus Merayo-Lloves
    Instituto Universitario Fernandez-Vega, Oviedo, Spain
  • Footnotes
    Commercial Relationships   Rosa Alvarado None; Belen Alfonso-Bartolozzi None; Jose F Alfonso None; Luís Fernández-Vega-Cueto None; Jesus Merayo-Lloves None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 3992. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rosa Alvarado, Belen Alfonso-Bartolozzi, Jose F Alfonso, Luís Fernández-Vega-Cueto, Jesus Merayo-Lloves; Allogeneic immunosafe plasma rich in growth factors as an alternative therapy in patients with refractory ocular surface disorders. Invest. Ophthalmol. Vis. Sci. 2023;64(8):3992.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Immunosafe plasma rich in growth factors (PRGF) is a well-known autologous blood-derived product manufactured through a standardized method with an evidence-based anti-inflammatory and regenerative role in ocular surface disorders; however, not all patients are candidates as donors due to age, systemic conditions, or technical issues for blood extraction. We performed a retrospective, observational clinical study to report the clinical outcomes of immunosafe PRGF from an allogeneic source for refractory ocular surface disorders.

Methods : Medical records from patients diagnosed with ocular surface disorders non-responsive to conventional therapy, who were given allogeneic immunosafe PRGF as compassionate treatment, were reviewed. Donors were healthy family members who were screened using standard tests used in blood bank screening to check for blood-borne diseases. Informed consent was obtained from patients and donors. Ocular Surface Disease Index (OSDI) questionnaire, Visual Analogue Score (VAS) of subjective symptoms, best-corrected visual acuity (BCVA), intraocular pressure (IOP), corneal fluorescein staining, Schirmer I test, tear break-up time (BUT), and conjunctival bulbar redness were recorded. Treatment-related side effects were also assessed. Wilcoxon signed-rank test was used for comparisons.

Results : Fifteen-five eyes from 8 patients with a mean age of 44.9±22.8 years (range: 11-82 years) were included. Most patients (6/8, 75%) were female, and offspring were the most frequent source of donors. Graft-versus-host disease and severe dry eye disease were the most common systemic and ocular conditions, respectively. Platelet and coagulation disorders and the lack of response to autologous blood-derived therapy were the most common indication. Over a mean 2-year follow-up period (range: 0.5–5 years), BCVA, VAS, and OSDI improved from the baseline values (p<0.05), and IOP remained unchanged (p=0.522). Corneal fluorescein staining and conjunctival bulbar redness reduced significantly (p<0.001), while an increase in Schirmer I test and BUT was observed (p<0.05). No side effects were recorded during the follow-up period.

Conclusions : Allogeneic immunosafe PRGF seems to be an effective and safe alternative treatment for refractory ocular surface disorders where patients were unsuitable for blood extraction. Further larger and controlled studies are needed.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.